How to Verify a Peptide's FDA Status

The Drugs@FDA database (accessdata.fda.gov/scripts/cder/daf/) is the FDA's official public repository of approved drug products. It contains information on every drug with an approved New Drug Application (NDA) or Biologics License Application (BLA), including approval dates, labeling, review documents, and manufacturing details.

To check a peptide, navigate to the Drugs@FDA search page and enter the generic name of the peptide (for example, "semaglutide" or "tirzepatide"). Use the active ingredient or generic name, not a brand name, for the most comprehensive results. If the peptide has an approved NDA or BLA, you will see one or more entries listing the approved products, their dosage forms, routes of administration, and approval history.

What to look for: An active NDA or BLA entry confirms the peptide is FDA-approved. Review the approval date, the approved indications (what the drug is approved to treat), and the current marketing status. If no results appear for the peptide name, it does not have FDA approval as a drug product. Note that some peptides may be approved under a slightly different name or salt form, so try variant spellings if your initial search returns no results.

DailyMed (dailymed.nlm.nih.gov) is a service provided by the National Library of Medicine that hosts FDA-approved prescribing information (package inserts) for marketed drugs. It is the most authoritative source for official drug labeling, including indications, dosing, contraindications, warnings, and adverse reactions.

Search DailyMed using the peptide's generic name or brand name. If official labeling exists, the peptide is a marketed drug product with FDA-approved prescribing information. The labeling document will include a structured product label (SPL) with sections covering clinical pharmacology, clinical studies, and patient counseling information.

What to look for: The presence of a DailyMed entry confirms the peptide is a marketed pharmaceutical product. Pay attention to the "Indications and Usage" section, which tells you exactly what the drug is approved to treat. The "Dosage and Administration" section provides FDA-approved dosing information. If no DailyMed entry exists for a peptide, it does not have official FDA-approved labeling and is not a marketed drug product in the United States.

The FDA Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations) is a comprehensive list of approved drug products along with their patent and exclusivity information. It is particularly useful for understanding whether generic versions of a peptide drug are available and how they compare to the reference listed drug.

Search the Orange Book online (accessdata.fda.gov/scripts/cder/ob/) by active ingredient. The results will show approved products, their application numbers, dosage forms, strengths, and therapeutic equivalence codes. For peptide biologics, note that biosimilar products are tracked through a separate system (the Purple Book) rather than the Orange Book.

What to look for: The Orange Book confirms which specific formulations and strengths of a peptide drug are approved. Therapeutic equivalence codes (such as AB, BX) indicate whether generic products are considered interchangeable with the brand-name version. Patent and exclusivity listings help explain why certain peptides may or may not have generic alternatives available. If a peptide does not appear in the Orange Book, it either is not approved or may be classified as a biologic rather than a drug.

ClinicalTrials.gov is a registry of clinical studies conducted around the world, maintained by the National Library of Medicine. Searching this database reveals whether a peptide is being studied in formal clinical trials, which provides important context about its evidence base even if it is not yet FDA-approved.

Enter the peptide name in the search bar and review the results. Filter by study status (recruiting, active, completed) to understand where the peptide is in the development pipeline. Look at the phase of the trials: Phase I studies focus on safety and dosing, Phase II on preliminary efficacy, and Phase III on large-scale efficacy and safety confirmation required for FDA approval.

What to look for: Multiple completed Phase III trials suggest a peptide has a robust evidence base and may be approaching or has already received approval. If a peptide has only Phase I or preclinical data, it is still early in development and its safety and efficacy in humans are not yet established. The absence of any clinical trial entries suggests the peptide has not been formally studied in humans under regulated conditions. Note that the existence of clinical trials does not imply the peptide is approved or safe for general use outside of those controlled trial settings.